PDF(Pubmed)
Abstract：
UNASSIGNED: Uveitis, as an extra-articular presentation, is found in 23% of patients with ankylosing spondylitis (AS) and is a challenging disease to treat.
UNASSIGNED: The authors presented a 32-year-old male to the out-hospital, complaining of recurrent anterior uveitis 8 years earlier in his left eye, and suffered from inflammatory lumber pain for 2 years. So a diagnosis of AS after the failure of many therapeutic strategies, 50 mg /month subcutaneous Golimumab was started with clinical remission of AS and uveitis.
UNASSIGNED: The American College of Rheumatology recommends the use of etanercept and adalimumab in the treatment of recurrent uveitis in AS patients. Similarly, the European League Against Rheumatism recommended using Infliximab, Adalimumab, or Certolizumab to prevent the recurrence of uveitis recurrence. Till now, a case about treating refractory uveitis with Golimumab in AS patients was published.
UNASSIGNED: Golimumab was found to be effective in the treatment of uveitis associated with spondyloarthritis refractory at least one immunosuppressive drug.
UNASSIGNED: The authors presented a 32-year-old male to the out-hospital, complaining of recurrent anterior uveitis 8 years earlier in his left eye, and suffered from inflammatory lumber pain for 2 years. So a diagnosis of AS after the failure of many therapeutic strategies, 50 mg /month subcutaneous Golimumab was started with clinical remission of AS and uveitis.
UNASSIGNED: The American College of Rheumatology recommends the use of etanercept and adalimumab in the treatment of recurrent uveitis in AS patients. Similarly, the European League Against Rheumatism recommended using Infliximab, Adalimumab, or Certolizumab to prevent the recurrence of uveitis recurrence. Till now, a case about treating refractory uveitis with Golimumab in AS patients was published.
UNASSIGNED: Golimumab was found to be effective in the treatment of uveitis associated with spondyloarthritis refractory at least one immunosuppressive drug.
摘要：
■葡萄膜炎，作为关节外的表现，在23％的强直性脊柱炎（AS）患者中发现，是一种具有挑战性的疾病。
■作者向医院外介绍了一名32岁的男性，抱怨8年前左眼复发性前葡萄膜炎,患有炎症性腰痛2年。因此，在许多治疗策略失败后诊断为AS，50mg/月皮下Golimumab开始治疗AS和葡萄膜炎的临床缓解。
■美国风湿病学会建议使用依那西普和阿达木单抗治疗AS患者复发性葡萄膜炎。同样，欧洲抗风湿病联盟建议使用英夫利昔单抗，阿达木单抗,或Certolizumab预防葡萄膜炎复发复发。到现在为止,发表了一例关于使用Golimumab治疗AS患者难治性葡萄膜炎的病例.
■发现戈利木单抗在治疗与脊柱关节炎相关的葡萄膜炎中至少有一种免疫抑制药物是有效的。
■作者向医院外介绍了一名32岁的男性，抱怨8年前左眼复发性前葡萄膜炎,患有炎症性腰痛2年。因此，在许多治疗策略失败后诊断为AS，50mg/月皮下Golimumab开始治疗AS和葡萄膜炎的临床缓解。
■美国风湿病学会建议使用依那西普和阿达木单抗治疗AS患者复发性葡萄膜炎。同样，欧洲抗风湿病联盟建议使用英夫利昔单抗，阿达木单抗,或Certolizumab预防葡萄膜炎复发复发。到现在为止,发表了一例关于使用Golimumab治疗AS患者难治性葡萄膜炎的病例.
■发现戈利木单抗在治疗与脊柱关节炎相关的葡萄膜炎中至少有一种免疫抑制药物是有效的。
